Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:45:01 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:BOLT from 2023-04-30 to 2024-04-29 - 19 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-21 16:05U:BOLTNews ReleaseBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
2024-02-27 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
2023-12-21 07:30U:BOLTNews ReleasePacira Appoints Frank D. Lee as Chief Executive Officer
2023-12-05 07:00U:BOLTNews ReleaseBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu ‚ ®
2023-11-09 16:05U:BOLTNews ReleaseBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-07 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
2023-10-23 10:30U:BOLTNews ReleaseBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
2023-10-18 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer ¢ € ™s 2023 Annual Meeting
2023-10-17 07:00U:BOLTNews ReleaseBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
2023-10-16 07:00U:BOLTNews ReleaseBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
2023-09-28 07:00U:BOLTNews ReleaseBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
2023-09-12 08:05U:BOLTNews ReleaseBolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
2023-09-05 16:15U:BOLTNews ReleaseBolt Biotherapeutics to Participate in September Investor Conferences
2023-08-07 16:10U:BOLTNews ReleaseBolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-03 07:30U:BOLTNews ReleaseBolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
2023-07-31 17:28U:BOLTNews ReleaseBolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
2023-05-30 08:00U:BOLTNews ReleaseBioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases
2023-05-25 17:05U:BOLTNews ReleaseBolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
2023-05-11 16:05U:BOLTNews ReleaseBolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update